Gabelli Funds LLC Purchases 406,656 Shares of Vitamin Shoppe Inc (NYSE:VSI)

Gabelli Funds LLC grew its position in Vitamin Shoppe Inc (NYSE:VSI) by 369.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 516,656 shares of the specialty retailer’s stock after buying an additional 406,656 shares during the period. Gabelli Funds LLC owned 2.15% of Vitamin Shoppe worth $3,369,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Gamco Investors INC. ET AL boosted its holdings in shares of Vitamin Shoppe by 1.1% in the 3rd quarter. Gamco Investors INC. ET AL now owns 176,000 shares of the specialty retailer’s stock valued at $1,148,000 after buying an additional 2,000 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Vitamin Shoppe in the 3rd quarter valued at about $2,318,000. California Public Employees Retirement System boosted its holdings in shares of Vitamin Shoppe by 5.8% in the 3rd quarter. California Public Employees Retirement System now owns 264,500 shares of the specialty retailer’s stock valued at $1,725,000 after buying an additional 14,500 shares in the last quarter. State of Alaska Department of Revenue boosted its holdings in shares of Vitamin Shoppe by 124.6% in the 3rd quarter. State of Alaska Department of Revenue now owns 11,834 shares of the specialty retailer’s stock valued at $77,000 after buying an additional 6,564 shares in the last quarter. Finally, VIEX Capital Advisors LLC boosted its holdings in shares of Vitamin Shoppe by 1,496.9% in the 2nd quarter. VIEX Capital Advisors LLC now owns 2,198,449 shares of the specialty retailer’s stock valued at $8,662,000 after buying an additional 2,060,782 shares in the last quarter. Institutional investors and hedge funds own 92.39% of the company’s stock.

Several brokerages recently commented on VSI. Zacks Investment Research lowered shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research report on Friday. ValuEngine raised shares of Vitamin Shoppe from a “sell” rating to a “hold” rating in a research report on Thursday, August 8th.

Shares of Vitamin Shoppe stock remained flat at $$6.47 during midday trading on Friday. 317,361 shares of the company traded hands, compared to its average volume of 536,362. The stock has a market capitalization of $155.69 million, a PE ratio of 24.88 and a beta of 1.59. The company has a current ratio of 1.18, a quick ratio of 0.23 and a debt-to-equity ratio of 2.37. The business has a 50-day moving average price of $6.56 and a two-hundred day moving average price of $5.44. Vitamin Shoppe Inc has a 52-week low of $3.32 and a 52-week high of $8.85.

Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings data on Thursday, August 8th. The specialty retailer reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.08. The firm had revenue of $270.88 million during the quarter, compared to analyst estimates of $278.60 million. Vitamin Shoppe had a negative net margin of 0.66% and a positive return on equity of 3.34%. As a group, sell-side analysts anticipate that Vitamin Shoppe Inc will post 0.55 earnings per share for the current fiscal year.

Vitamin Shoppe Profile

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

Featured Article: How is inflation measured?

Institutional Ownership by Quarter for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit